Whether the inhibition of IRE1α/XBP1 axis and PARP could be more cytotoxic than the single treatments against PEL was also evaluated, to assess if this therapeutic strategy could be widened against c-Myc-and gammaherpesvirus-driven B-cell lymphomas. Here, MYC is linked to B-cell non-Hodgkin lymphoma.